A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. .

DM1 - Pharmacology:

DM1 has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: DM1 forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes.

DM1 for patients

Patient Information:

DM1 is not recommended to patients who are pregnant and breast feeding because of the serious side

Check with your doctor immediately if you experience unusual bleeding or bruising, black stool, blood in
urine or stool.

Avoid contact with persons with infections. Check with you doctor immediately if you experience fever,
chill, cough or painful or painful or difficult urination.

Wash hands after you touch the medication.

DM1 Interactions

Use of Cerubidine in a patient who has previously received doxorubicin increases the risk of cardiotoxicity. Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or Cerubidine. Cyclophosphamide used concurrently with Cerubidine may also result in increased cardiotoxicity.

Dosage reduction of Cerubidine may be required when used concurrently with other myelosuppressive agents.

Hepatotoxic medications, such as high-dose methotrexate, may impair liver function and increase the risk of toxicity.

DM1 Contraindications

Cerubidine is contraindicated in patients who have shown a hypersensitivity to it.

Generic name, Overdose, Half Life DM1, Food Interactions, Chemical, etc..

DM1 see also

Chemical structure:
O O O O O N O O O O O H H H H H H H H H H H H H H H H H H H H H H H H H H H H H C27H29NO10 2D chemical structure C27H29NO10 SVG | 2D structure chemical names, chemical properties, classification C27H29NO10